NeuBase Therapeutics (NASDAQ: NBSE)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.300 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of NeuBase Therapeutics (NASDAQ: NBSE) through any online brokerage.
Other companies in NeuBase Therapeutics’s space includes: Vincerx Pharma (NASDAQ:VINC), Cabaletta Bio (NASDAQ:CABA), Cellectar Biosciences (NASDAQ:CLRB), T2 Biosystems (NASDAQ:TTOO) and Monopar Therapeutics (NASDAQ:MNPR).
The latest price target for NeuBase Therapeutics (NASDAQ: NBSE) was reported by HC Wainwright & Co. on Tuesday, May 31, 2022. The analyst firm set a price target for 10.00 expecting NBSE to rise to within 12 months (a possible 1076.47% upside). 2 analyst firms have reported ratings in the last year.
The stock price for NeuBase Therapeutics (NASDAQ: NBSE) is $0.85 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for NeuBase Therapeutics.
NeuBase Therapeutics’s Q3 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for NeuBase Therapeutics.
NeuBase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.